Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2005-09-06
2005-09-06
Andres, Janet (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
C424S085200, C424S145100, C424S198100, C530S350000
Reexamination Certificate
active
06939545
ABSTRACT:
Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
REFERENCES:
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5536637 (1996-07-01), Jacobs
patent: 5674487 (1997-10-01), Smith et al.
patent: 5837232 (1998-11-01), De Waal Malefyt et al.
patent: 5863796 (1999-01-01), Moore et al.
patent: 6225117 (2001-05-01), Gately et al.
patent: 6274710 (2001-08-01), Dumoutier et al.
patent: 6331613 (2001-12-01), Dumoutier et al.
patent: 6359117 (2002-03-01), Dumoutier et al.
patent: 6551799 (2003-04-01), Gurney et al.
patent: 2001/0006637 (2001-07-01), Akahoshi et al.
patent: 2001/0024652 (2001-09-01), Dumoutier et al.
patent: 2002/0012669 (2002-01-01), Presnell et al.
patent: 2002/0102723 (2002-08-01), Gurney et al.
patent: 2002/0187523 (2002-12-01), Tang et al.
patent: 2003/0012788 (2003-01-01), Renauld et al.
patent: 2003/0170823 (2003-09-01), Presnell et al.
patent: 2004/0023341 (2004-02-01), Wenfeng et al.
patent: 2004/0110189 (2004-06-01), Dumoutier et al.
patent: 2004/0152125 (2004-08-01), Presnell et al.
patent: 2004/0180399 (2004-09-01), Renauld et al.
patent: WO 94/01548 (1994-01-01), None
patent: WO 99/61617 (1999-12-01), None
patent: WO 00/24758 (2000-05-01), None
patent: WO 2000/24758 (2000-05-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 00/73457 (2000-12-01), None
patent: WO 00/77037 (2000-12-01), None
patent: WO 01/46422 (2001-06-01), None
patent: WO 02/10393 (2002-02-01), None
patent: WO 02/10393 (2002-02-01), None
patent: WO2002/16611 (2002-02-01), None
Radaeva et al. (2004), Hepatology 39(5): 1332-1342.
Simon L.S. et al. (2000), New and future drug therapies for rheumatoid arthritis, Rheumatology 39 (suppl. 1): 36-42.
Llorente L. et al. (2000), Clinical and Biological Effects of Anti-Interleukin-10 Monoclonal Antibody Administration in Systemic Lupus Erythematosus, Arthritis & Rheumatism 43(8): 1790-1800.
van den Berg W. (1998), Joint inflammation and cartilage destruction may occur uncoupled, Springer Semin Immunopathol 20: 149-164.
Mahairas G., et al. Database EST. Accession No. AQ104025. Aug. 28, 1998.
Waterston R., et al. Database GenEmbl. Accession No. AC006734. Feb. 25, 1999.
Wilson R., et al. J. Mol. Biol. 261:155-172, 1996.
Bork, et al. Trends in Genetics 12:425-427, 1996.
Vukicevic, et al. PNAS USA 93:9021-9026, 1996.
Massague J. Cell 49:437-8, 1987.
Pilbeam, et al. Bone 14:717-720, 1993.
Skolnick, et al. Trends in Biotech. 18:34-39, 2000.
Dumoutier, et al. (2000), “Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9,” J. of Immunol. 164:1814-1819.
Syrbe, et al. (1999) Springer Seminars in Immunopathology, 21:263-85.
Dumoutier, L., et al. GenBank Accession No. NM_016971 for mus musculus interleukin 10-related T cell-derived inducible factor (Iltif). Jun. 8, 2000.
Aoki, I., et al. “Comparison of the amino acid and nucleotide sequences between human and two guinea pig major basic proteins,” FEBS Lett. 282(1):56-60, 1991.
Dumoutier, L., et al., “Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor,” PNAS 97(18):10144-9, 2000.
Dumoutier, L., et al., “IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes,” Genes Immun. 1:488-494, 2000.
Ozaki, T., et al. GenBank Accession No. D13973 for Dictyostelium discoideum DNA for Dp87 protein, 1993. Feb. 1, 2000.
Aoki, I., et al. GenBank Accession No. P35709 for Eosinophil granule major basic protein 2 percursor (mbp-2). May 30, 2000.
Xie, M., et al GenBank Accession No. AF279437 forHomo sapiensinterleukin 22 (IL22). Oct. 9, 2000.
Dumoutier, L., et al. GenBank Accession No. AJ294727 for Mus musculus ILTIFa gene for IL TIE alpha protein (IL-21), exons 1a 5. Dec. 21, 2000.
Dumoutier, L., et al. GenBank Accession No. NP_065386 for Interleukin 22; interleukin 21; IL-10-related T-cell-derived inducible factor (Homo sapiens). Nov. 2, 2000.
Ozaki, T., et al., “Developmental regulation of transcription of a novel prespore-specific gene (Dp87) in Dictyostelium discoideum,” Development. 117(4): 1299-308, 1993.
Sambrook, J., et al. Molecular Cloning. A Laboratory Manual, 2d ed. Cold Spring Harbor Laboratory Press, 1989, Ch. 17.
Xie, M.H., et al. “Interleukin IL-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R,” J. Biol. Chem. 275(40):31335-9, 2000.
Dumoutier, L., et al: “Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), A Novel Cytokine Structurally Related to IL-10 and Inducible By IL-9” Journal of Immunology, Blackwell Scientific Publications, GB, vol. 164, 2000, pp. 1814-1819.
Dumoutier, L., et al: “Human Interleukin-10-Related T-Cell-Derived Inducible Factor: Molecular Cloning and Functional Characterization as an Hepatocyte-Stimulating Factor” Proceedings of the National Academy of Sciences of USA, National Academy of Science. Washington, US, vol. 97, No. 18, Aug. 29, 2000, pp. 10144-10149.
Xie, M-H et al: “Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R” Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US, vol. 275, No. 40, Oct. 6, 2000, pp. 31335-31339.
Kotenko, Sergei V. et al: “Identification of the functional interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes” Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US, vol. 276, No. 4, Jan. 26, 2001, pp. 2725-2732.
Dumoutier, L., et al: “IL-TIF induces acute phase reactant production by hepatocytes through IL-10Rbeta.” Immunology Letters, vol. 73, No. 2-3 Sep. 2000, p. 261.
Lambert, A. et al: “Novel cytokine IL-22 administrated by adenovirus vector or as recombinant purified protein induces acute-phase responses and renal tubular basophilia in female C57BL/6 mice.” Toxicologic Pathology, vol. 29, No. 6, Nov. 2001. p. 712.
Bork, P., Genome Research 10:398-400, 2000.
Doerks, et al, Trends in Genetics 14:248-250, 1998.
Smith, et al, Nature Biotechnology 15:1222-1223, 1997.
Brenner, S.E., Trends in Genetics 15:132-133, 1999.
Mahairas, et al., PNAS, USA, 96(17) 9739-9744 (1999).
Xie, M-H, et al (2000) J. Biol. Chem. vol. 275(40):31335-31339.
Dumoutier, et al (2000) PNAS 97(18): 10144-10149.
R&D Systems, Catalog NR, AF582, XP002307633, “Anti-Mouse IL-22 Antibody”, Aug. 22, 2002.
Kotenko, Sergei, “The Family of IL-10-Related Cytokines and Recepators: Ralated, But to What Extent?”, Cytokine and Growth Factor Reviews, vol. 13, No. 3, Jun. 2002, pp. 223-240.
Resmini, Christine, et al, “An Anti-Murine IL-22 Monoclonal Antibody Decreases Disease Severity in a Murine Model of Collagen Induced Arthritis”, European Cytokine Network, vol. 14, No. Supplement 3, Sep. 2003, p. 129 and Annual Meeting of the International Cytokine Society; Dublin, Ireland, Sep. 20-24, 2003, ISSN: 1148-5493.
Li, J., et al, “Temporal Associations Between Interleukin 22 and the Extracellular Domains of IL-22R and IL-10R2”, International Immunopharmacology, Elsevier, Amsterdam, NL, vol. 4, No. 5, May 2004, pp. 693-708.
International Search Report for International Application No. PCT/US2004/020833.
Fouser Lynette
Jacobs Kenneth
Pittman Debra D.
Spaulding Vikki
Xuan Dejun
Andres Janet
Collazo Diana M.
Genetics Institute LLC
Hunnicutt Rachel K.
Ryan M. Andrea
LandOfFree
Composition and method for treating inflammatory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating inflammatory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating inflammatory disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387588